tbuckley/cabot-search huggingface dataset:
FRI0229 Evaluation of Patient Acceptable Symptom State in Patients with Axial Spondylarthritis; Similar Thresholds for Radiographic and Non-Radiographic Subgroups
Authors: P. Cetin, G. Sen, G. Kenar, H. Yarkan, B. Zengin, I. Sari, M. Birlik, F. Onen, N. Akkoc
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being. A few studies have assessed PASS in patients with ankylosing spondylitis (AS), but it is not known whether the results of those studies apply also to the group of non-radiographic (nr) axial spondylarthritis (axSpA) <h3>Objectives</h3> To estimate the PASS values for disease activity and several patient reported outcomes both in the whole group of axSpA and in the two subgroups of AxSpA. <h3>Methods</h3> This single-center cross-sectional analysis included patients fulfilling the ASAS criteria for axSpA, who have been registered in our local database. All patients responded to the global yes/no question for PASS. A variety of other outcome measures in regard with global scales, disease activity, functional status, health status and quality of life were collected at the same time. The thresholds at which patients rated themselves in PASS for disease activity (BASDAI and ASDAS) and for each of the assessed patient self-reported outcome measures were estimated using the 75th centile (25th centile for SF 36)estimation and receiver operating characteristic (ROC) analyses in the whole group, as well as in each subgroup of axSpA. Contributors which can affect PASS were evaluated with logistic regression analysis. <h3>Results</h3> The analysis was based on 356 axSpA patients (261 AS, 95 nr-axSpA) with a mean age of 42.2±12.0 years and mean disease duration of 14.7±10.8 years. Of the patients with axSpA, 271 (%76.1) considered themselves in PASS (76.6% in AS, 74.7% in nr-axSpA). PASS thresholds for disease activity and all other assessed outcome measures were shown in table and there were not significant difference between AS and nr-axSpA group. PASS cut-off points for BASDAI, BASFI and HAQ identified by the 75th percentile method were slightly higher than those determined by the ROC analysis, but similar for the rest of the outcome measures. The patients with an acceptable status had significantly lower mean disease activity scores and good results with the all outcome measures. PASS had no relationship with age, sex, disease duration and education (years) in logistic regression analysis. Of the axSpA patients with BASDAI (≥4), 61.4% and those with ASDAS (&gt;3.5), 50% rated themselves in PASS, whereas 5.5% of the patients with a BASDAI score &lt;2, and 4.5% of those with ASDAS &lt;1.2 were not in PASS. <h3>Conclusions</h3> PASS thresholds for disease activity and outcome measures were similar to the figures previously reported in some studies with no apparent difference between patients with AS and nr-axSpA. However, more than half the Turkish axSpA patients considered themselves in PASS, which needs to be evaluated in further studies. <h3>Disclosure of Interest</h3> None declared
Memorial II
Authors: Janet M. Torpy
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Autoadaptive motion modelling for MR-based respiratory motion estimation
Authors: Christian F. Baumgartner, Christoph Kolbitsch, Jamie R. McClelland, Daniel Rueckert, Andrew P. King
Journal: Medical Image Analysis (2016)

Respiratory motion poses significant challenges in image-guided interventions. In emerging treatments such as MR-guided HIFU or MR-guided radiotherapy, it may cause significant misalignments between interventional road maps obtained pre-procedure and the anatomy during the treatment, and may affect intra-procedural imaging such as MR-thermometry. Patient specific respiratory motion models provide a solution to this problem. They establish a correspondence between the patient motion and simpler surrogate data which can be acquired easily during the treatment. Patient motion can then be estimated during the treatment by acquiring only the simpler surrogate data. In the majority of classical motion modelling approaches once the correspondence between the surrogate data and the patient motion is established it cannot be changed unless the model is recalibrated. However, breathing patterns are known to significantly change in the time frame of MR-guided interventions. Thus, the classical motion modelling approach may yield inaccurate motion estimations when the relation between the motion and the surrogate data changes over the duration of the treatment and frequent recalibration may not be feasible. We propose a novel methodology for motion modelling which has the ability to automatically adapt to new breathing patterns. This is achieved by choosing the surrogate data in such a way that it can be used to estimate the current motion in 3D as well as to update the motion model. In particular, in this work, we use 2D MR slices from different slice positions to build as well as to apply the motion model. We implemented such an autoadaptive motion model by extending our previous work on manifold alignment. We demonstrate a proof-of-principle of the proposed technique on cardiac gated data of the thorax and evaluate its adaptive behaviour on realistic synthetic data containing two breathing types generated from 6 volunteers, and real data from 4 volunteers. On synthetic data the autoadaptive motion model yielded 21.45% more accurate motion estimations compared to a non-adaptive motion model 10 min after a change in breathing pattern. On real data we demonstrated the method's ability to maintain motion estimation accuracy despite a drift in the respiratory baseline. Due to the cardiac gating of the imaging data, the method is currently limited to one update per heart beat and the calibration requires approximately 12 min of scanning. Furthermore, the method has a prediction latency of 800 ms. These limitations may be overcome in future work by altering the acquisition protocol.
Effects of Some Metabolic Inhibitors on the Growth and Lipide Composition of Earle's Strain L Cells&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;,&lt;xref ref-type="fn" rid="fn2"&gt;3&lt;/xref&gt;
Authors: Relda Cailleau, Shirley Moss, Benjamin V. Siegel
Journal: JNCI Journal of the National Cancer Institute (1956)

Effects of Some Metabolic Inhibitors on the Growth and Lipide Composition of Earle's Strain L Cells, Get access Relda Cailleau, Relda Cailleau Department of Biochemistry and Virus Laboratory, University of California, Berkeley, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Shirley Moss, Shirley Moss Department of Biochemistry and Virus Laboratory, University of California, Berkeley, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar Benjamin V. Siegel Benjamin V. Siegel Department of Biochemistry and Virus Laboratory, University of California, Berkeley, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 4, February 1956, Pages 1011–1019, https://doi.org/10.1093/jnci/16.4.1011 Published: 01 February 1956 Article history Received: 31 August 1955 Published: 01 February 1956
Reply: Different Definitions of Lung Recruitment by Computed Tomography Scan
Authors: Luciano Gattinoni, Eleonora Carlesso, Davide Chiumello, Massimo Cressoni
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Answering their questions and comments gives us the opportunity to better clarify some aspects of our article (1).The questions and comments of Dr. Chen and colleagues focus on the use of a threshold of 2500 Hounsfield units (HU) to define recruitment.The increase in poorly aerated tissue increasing positive end-expiratory pressure (PEEP) in the most severe patients is not a result of "derecruitment" but likely, as Dr. Chen and colleagues also suggested, of a transformation of not-aerated tissue (threshold of 2100 HU) in poorly aerated tissue.Basically, in our study (see Table E6 in the online supplement [we are sorry for the wrong title]), we showed that a proper threshold for the voxel-by-voxel analysis is between 2100 and 2200 HU.Within this range, we measure the pulmonary units that would likely undergo opening and closing at PEEP lower than 15 cm H 2 O. Lower levels of thresholds would be misleading, as shown in Figure 1.Different is the use of 2500 HU thresholds in the anatomybased analysis of the original Rouby's method (2).Rouby's method
Choreoathetosis associated with lithium: case report and literature review
Authors: C F Zorumski, G L Bakris
Journal: American Journal of Psychiatry (1983)

T he use of lithium can be limited by a variety of side effects, including neurotoxicity. The neurologic side effects associated with therapeutic levels of lithium include tremor and cogwheel rigidity (1). Toxic serum lithium levels can produce confusion, cerebellar signs (ataxia and dysarthria), and seizures (2). These toxic symptoms are usually reversible with dose reduction, although some patients develop persistent cerebellar abnormalities (3). Choreoathetosis, a symptom complex characterized by either hyperkinetic, irregular random jerks or slow, writhing movements, is a side effect of various agents (4). Although commonly seen as a manifestation of tardive dyskinesia secondary to chronic neumoleptic use, chomeoathetosis is rarely reported as a side effect of lithium. In this paper we review the reported cases of choreoathetosis associated with lithium and describe a patient who developed choreoathetosis as part of a syndrome of lithium toxicity.
PTU-149 Disease specific outcomes in patients following peg insertion – a single centre 10 year experience
Authors: J Colby, NE Burch
Journal: Gut (2015)

<h3>Introduction</h3> Insertion of a percutaneous endoscopic gastrostomy (PEG) in patients with dysphagia to enable provision of artificial nutrition and hydration is a widely recognised and commonplace technique. Although there are numerous small outcome studies highlighting overall risk of complications post insertion, there are very little data which reflect disease specific outcome following PEG insertion. We retrospectively evaluated disease specific 30-day mortality in a large cohort of patients undergoing PEG insertion. <h3>Method</h3> A 10 year retrospective evaluation of all PEGs inserted at University Hospitals Coventry and Warwickshire was performed with patients identified from the Nutrition Team database. All patients between Sept 2004 and Aug 2014 were included. All patients who died within 30-days of PEG insertion were identified. Patient notes, electronic records, and death certificates (where available) were evaluated with particular attention to: demographics, primary diagnosis, indication for PEG, and co-morbidities. <h3>Results</h3> A total of 1518 PEGs were inserted over 10 years (59% male, 41% female, age range 17–99 yrs; mean age 67). Overall 30-day mortality was 7.6% (n = 115). Procedure related mortality was 1% (n = 19), due to: immediate aspiration post procedure (0.2%); peritonitis (0.6%); cardiac event (0.1%); and 'PEG pulled out' (0.3%). Indications for PEG included: CVA (38%, n = 579); head and neck (H&amp;N) cancer (29%, n = 435); neurosurgical/ traumatic brain injury (12%, n = 186); neurodegenerative disease (10%, n = 154); learning disability (2.8%); cancer (1.8%); dementia (1.1%); renal (0.8%) post-cardiothoracic surgery (0.5%); and other (4%). Thirty day mortality by disease group was highest in patients with Dementia (23.5%), Cancer (non-H&amp;N) (18.5%), Learning disability (14%), and CVA (12.3%). Lowest 30-day mortality was seen in H&amp;N cancer (2.5%), and neurosurgical/neurodegenerative disease (4.4%). When comparing 30-day mortality in the stroke cohort in the first 5 years, compared to second 5 years, there was a reduction in mortality of almost 50% (15.3 vs 7.9%). This is despite similar age range and number of procedures. Cause of death in CVA patients in the first 5 year period was aspiration pneumonia in 73% vs. 58% in the second period. <h3>Conclusion</h3> Our audit highlights a significant variation in disease related 30-day mortality following PEG insertion in the largest published cohort (to our knowledge). This supports the need to consider disease specific factors when assessing and consenting patients for PEG insertion with respect to expected risks and outcome. Our findings emphasise the need for a robust, prospective, multi-centre audit of PEGs to clarify disease related outcomes in the UK. <h3>Disclosure of interest</h3> None Declared.
The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?
Authors: Rishi Jain, Michelle J. Savage, Andrea D. Forman, Reetu Mukherji, Michael J. Hall
Journal: Journal of the National Comprehensive Cancer Network (2016)

Through tumor genomic profiling (TGP), existing and novel treatments can be selected to better target the specific dysregulated molecular pathways that drive growth and spread of a patient's tumor. Although the primary purpose of TGP is to detect targetable somatic mutations for treatment, TGP may also uncover germline mutations with important implications for patients and family members. Oncology care providers should be aware of the hereditary cancer risks associated with genes commonly tested by TGP. Further, patients should be informed about the possible discovery of hereditary cancer risk information and the relevance of this information to their health and that of family members, and should have their preferences toward further evaluation of hereditary risk information that could be revealed by TGP documented in the medical record and followed.
Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Authors: P. Zatloukal, D. S. Heo, K. Park, J. Kang, C. Butts, D. Bradford, S. Graziano, B. Huang, D. Healey
Journal: Journal of Clinical Oncology (2009)

8071 Background: Pts diagnosed with advanced NSCLC with good performance status typically receive platinum-based chemotherapy; however, no approved maintenance therapy exists. Tremelimumab, a fully human anti-CTLA4 mAb, is associated with durable responses in some pts with metastatic melanoma. Methods: This open-label, randomized, multicenter, phase II clinical trial evaluating efficacy and safety of tremelimumab as maintenance therapy was conducted in pts with locally advanced or metastatic NSCLC with ECOG performance status ≤1. Pts treated with ≥4 cycles of first-line platinum-based therapy resulting in either stable disease (SD) or response per RECIST were eligible and were randomized 3–6 weeks after prior therapy. Pts received 15 mg/kg IV tremelimumab Q90D or BSC until disease progression. Primary endpoint was progression-free survival (PFS) at 3 months. Secondary endpoints included safety, objective response rate, and 1-year survival. Results: Eighty-seven pts received tremelimumab (n=44) or BSC (n=43). Nine (20.9%; 90% CI: 11.4%, 33.7%) pts receiving tremelimumab and 6 (14.3%; 90% CI: 6.4%, 26.3%) pts receiving BSC were progression free at 3 months. Among pts receiving tremelimumab, there were 2 (4.8%) partial responses and 7 (16.6%) SDs, compared with 0 and 6 (14.3%) pts receiving BSC, respectively. Treatment-related adverse events (AEs) were observed in 27 (61.4%) pts receiving tremelimumab and 3 (7.0%) receiving BSC. Nine pts (20.5%) receiving tremelimumab reported grade 3 or 4 AEs compared with 0 patients receiving BSC. The most common grade 3 or 4 AEs attributed to tremelimumab were diarrhea and colitis (n=4, 9.1%). Conclusions: In pts with advanced NSCLC and good performance status receiving platinum-based first-line therapy, single-agent tremelimumab was tolerable, with safety consistent with prior studies. Although PFS analysis did not demonstrate superiority of tremelimumab over BSC, the 4.8% objective response rate seen only in the investigational arm may support future combination studies. Analysis of 1-year survival is forthcoming. [Table: see text]
Endemic presence of Salmonella enterica serotype Cerro in southern Italy
Authors: C Mammina, L Cannova, S CarfiPavia, A Nastasi
Journal: Eurosurveillance (2000)

Molecular typing of salmonella strains isolated between 1997 and 1999 in southern Italy and carried out by the Southern Italy Centre for Enteric Pathogens, has shown a high frequency of Salmonella enterica serotype Cerro. This serotype is extremely rare i
Suicide prevention strategies revisited: 10-year systematic review
Authors: Gil Zalsman, Keith Hawton, Danuta Wasserman, Kees van Heeringen, Ella Arensman, Marco Sarchiapone, Vladimir Carli, Cyril Höschl, Ran Barzilay, Judit Balazs, György Purebl, Jean Pierre Kahn, Pilar Alejandra Sáiz, Cendrine Bursztein Lipsicas, Julio Bobes, Doina Cozman, Ulrich Hegerl, Joseph Zohar
Journal: The Lancet Psychiatry (2016)
PWE-354 Can we safely carry out less intensive colonoscopy surveillance in patients post curative colorectal cancer resection?
Authors: EL Johnston, A Zacks, S Shaheen, F Ataklte, M George, JM Dunn
Journal: Gut (2015)

<h3>Introduction</h3> London Cancer Alliance (LCA) published their guidelines on colorectal cancer (CRC) in September 2014.<sup>1</sup>They highlight that intensive colonoscopic follow up does not have a significant effect on survival. As a result the guidelines recommend a less rigorous regimen than we currently adopt; a full colonoscopy at 1 year and then 5 years post operatively if a complete procedure was done at diagnosis and no abnormalities are detected during surveillance. The aim of this study is to retrospectively determine whether any recurrence or new cancers would have been missed should the guidelines have been implemented. <h3>Method</h3> An endoscopy database search of patients who underwent a colonoscopy for CRC surveillance from 1<sup>st</sup>January 2008 to 31<sup>st</sup>December 2013 was carried out. The follow up interval of the cohort diagnosed and treated in 2007 was then assessed for 5 years using clinical records. <h3>Results</h3> During the 6-year period 495 colonoscopies were carried out for CRC surveillance. From these, 49 patients were identified who had been diagnosed and treated in 2007. Six patients had polyps found during surveillance and followed up according to the British Society of Gastroenterology (BSG) polyp guidelines,<sup>2</sup>so were removed from analysis. Of the remaining 43 patients, 27 (62.8%) were discharged after 5 years of follow up, 12 (27.9%) died and 4 (9.3%) remain under follow up due to recurrent disease diagnosed either on radiological imaging or during colonoscopy. Over a 5-year time period 71 colonoscopies were carried out on 31 patients, averaging at 2.3 colonoscopies per patient. 15 patients had 3 or more colonoscopies in the study period. Recurrence was only seen on 2 colonoscopies, 1 year post surgery in one patient and 5 years post surgery in the other, both of which would have been identified if the new LCA guidelines were adopted. <h3>Conclusion</h3> In this retrospective study, adoption of the LCA guidelines for CRC surveillance post curative surgery does not increase the miss rate for recurrence. In addition, 15 patients (48.4%) would have had fewer unnecessary colonoscopies, reducing risk to the patient and cost. A prospective study is warranted. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> LCA Colorectal Cancer Clinical Guidelines. September 2014. http://www.londoncanceralliance.nhs.uk/media/83350/lca_colorectalclinicalguidelines2014.pdf Cairns S, Scholefield J, Steele R, <i>et al</i>. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666–690
Glycogen Content of Cell Suspensions Prepared From Massive Tissue Culture. II. Comparison of Fourteen Cell Strains After Long Cultivation &lt;italic&gt;In Vitro&lt;/italic&gt;&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: E. V. Peppers, B. B. Westfall, W. R. Earle
Journal: JNCI Journal of the National Cancer Institute (1959)

Thirteen mouse-tissue cell strains and one cell strain derived from human epidermal tissue were examined for their glycogen content after rapid proliferation for years in vitro. Strain NCTC 721 of mouse-liver epithelial origin, which was found to synthesize glycogen several years ago, still has this capacity. Strain NCTC clone 1469 derived from strain 721 of mouse liver also synthesizes glycogen. About 2 percent of the cultures from this clone gave rise to hepatomas at the site of injection when the cultures were returned to mice of the strain from which 721 originated. One of the hepatoma epithelial cell lines obtained 4 years after return to culture in vitro attained no detectable glycogen content, and the hepatomas derived from the cultures on re-injection in the animal had no glycogen. The human-skin strain NCTC 2198 contained glycogen. This strain had been grown from the epidermis of a 53-year-old man. Seven cell strains derived from mouse connective tissue were negative for glycogen. Three clones derived from mouse mammary carcinoma were likewise negative for glycogen.